2025年11月6日， 健康元 （ 600380 ）药业集团（600380.SH）宣布，其与拜耳合作开发的全球首创PREP抑制剂正式启动IIa期临床试验，首位慢性阻塞性肺疾病（COPD）患者顺利入组。

-Ritedose is the development partner and manufacturer of Ohtuvayre (ensifentrine)*, the first inhaled product with a novel mechanism of action in more than 20 years for the maintenance treatment of ...

November marks COPD Awareness Month, and advocates this year will focus on action, and education about chronic obstructive ...

Check this table to make sure you can use your COPD inhalers together Medically reviewed by Sanja Jelic, MD Most people with chronic obstructive pulmonary disease (COPD) use an inhaler every day to ...

GSK and Empirico ink license agreement for clinical-stage, first-in-class oligonucleotide candidate to treat respiratory diseases: London, UK Wednesday, October 29, 2025, 09:00 Hr ...

Shortly following the announcement of its acquisition of Syndivia’s ADC, GSK entered into a worldwide exclusive license ...

I was diagnosed with COPD last year after struggling with multiple symptoms. I quit smoking over 10 years ago, but I’m ...

Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases Through this acquisition Merck will add ...

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)-- Aptar Digital Health, part of Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced a strategic ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, today ...

The COPD Action Alliance applauds Governor Bill Lee for proclaiming November as Chronic Obstructive Pulmonary Disease (COPD) Awareness Month in Tennessee, recognizing the urgent need for greater ...